Jared Kaltwasser

Nerandomilast slowed disease progression at 2 doses compared with placebo among US participants in the trial.

The study underscores the importance of repeat testing in cases where myelin oligodendrocyte glycoprotein immunoglobulin G tests are borderline.

Though patients with type 2 diabetes or chronic kidney disease (CKD) face a greater risk of heart failure (HF) following acute myocardial infarction (AMI), patients without those comorbidities also benefit from empagliflozin.

Real-world data suggest metabolic dysfunction-associated steatotic liver disease is also associated with higher all-cause mortality.

Previous research has evaluated PD-1/PD-L1 immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC), but research in the setting of limited-stage disease is sparse.

Radiomic assessment has been used to distinguish multiple sclerosis from similar disorders, and it might also be useful in identifying MS stages and subtypes.

A new analysis suggests links between ZRSR2 loss and JAK2 V617R disease progression are indirect and complex.

Cardiac adverse events were lower among patients taking zanubrutinib compared with ibrutinib in the real-world setting.

New reporting suggests obesity and diffuse large B-cell lymphoma (DLBCL) have shared genetic risk factors.

Multidrug combinations may counteract the role of cytokines in drug resistance, a new review article explains.

Treatment options for patients with small cell lung cancer (SCLC) who survive to a third line of therapy are insufficient, authors of a new study argue.

Glucagon-like peptide 1 receptor agonists improved disease activity, body weight, and cholesterol in patients with rheumatoid arthritis.

Questions remain related to which patients with diffuse large B-cell lymphoma (DLBCL) benefit most from radiotherapy and at what dose.

LAG-3 expression appears to be significantly elevated in patients with small cell lung cancer (SCLC).

Atomic force microscopy successfully identified nanomechanical changes in fibrotic lung tissue.

A Mendelian randomization study suggests Actinomyces plays a role in idiopathic pulmonary fibrosis, mediated by circulating inflammatory proteins.

Nanopore sequencing of chronic lymphocytic leukemia (CLL) may be a particularly good fit in under-resourced areas due to its lower cost and smaller laboratory footprint.

Early research has identified several antigens that could help facilitate the use of chimeric antigen receptor T cells in small cell lung cancer.

The class of diabetes drug has a protective effect on the kidneys for reasons beyond glucose control.

New treatment options are needed for patients with accelerated-phase or blast-phase myeloproliferative neoplasms (MPNs) ineligible for standard care.

Biomarkers like neutrophil-to-lymphocyte ratio could help predict treatment response to immune checkpoint inhibitors in certain patients with soft tissue sarcoma.

A wearable cough monitor generated clinically useful cough data, but patients only wore the device about half of the days of the study period.

Patients with immunoglobulin M-type monoclonal gammopathy did not experience a survival benefit from targeted therapies, a study found.

Second primary malignancies in patients with small cell lung cancer are often misdiagnosed as distant metastases.

High-risk patients who cannot find a matched sibling or matched unrelated donor may achieve a similar benefit from a haploidentical donor.

Patients with essential thrombocythemia live with a risk of developing serious bleeding complications, a new study explains.

A case series suggests using minimal residual disease to trigger anti-CD20 therapy for chronic lymphocytic leukemia (CLL) can add years to some patients’ lives.

A new report identified 11 additional high-frequency mutations in small-cell lung cancer.

Only a fraction of countries in the world have designated chronic kidney disease as a health priority.

Patients with progressive pulmonary fibrosis had longer survival with antifibrotic therapy, but only if they met a key criteria.